Pharmacyte Biotech, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Pharmacyte Biotech, Inc., a Nevada corporation, on April 27, 2015. The report addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors to fill a vacancy created in October 2014.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation arrangement for the newly appointed director:
- Quarterly Cash Retainer: $9,000 per calendar quarter.
- Stock Option Grant: 250,000 shares of common stock, fully vested.
- Option Exercise Price: $0.159 per share (fair market value on the date of grant).
Material Changes
The primary material change reported is the appointment of Thomas Liquard to the Board of Directors. Mr. Liquard has been assigned to the Audit Committee and will serve as its Chairperson. This appointment replaces the vacancy left by the departure of certain board members in October 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, future guidance, or specific risk factors. The document is strictly limited to the disclosure of the director appointment and the associated compensatory arrangements. No unusual items or contingencies were reported.
Investor Verification Checklist
- Verify the current status of the 250,000 stock options granted to Thomas Liquard and their impact on total share count.
- Confirm the composition of the Audit Committee following Mr. Liquard's appointment as Chairperson.
- Review the full text of the Letter Agreement (Exhibit 10.1) for any additional terms not summarized in the 8-K.
- Check subsequent filings for any further changes to the Board of Directors or executive compensation.